Enasidenib
Enasidenib (pronounced as en-uh-sid-uh-nib) is a medication used in the treatment of acute myeloid leukemia (AML). It is specifically used for patients with an isocitrate dehydrogenase 2 (IDH2) mutation, which is a type of genetic mutation found in some AML patients.
Etymology
The name "Enasidenib" is derived from the drug's chemical structure. The "en" prefix refers to the presence of a double bond in the molecule, "asid" is a reference to the drug's inhibitory action on the enzyme aspartate, and "nib" is a common suffix used in the names of kinase inhibitors, indicating the drug's mechanism of action.
Pharmacology
Enasidenib works by inhibiting the mutated IDH2 enzyme, which is responsible for the production of an oncometabolite that promotes the growth of cancer cells. By inhibiting this enzyme, Enasidenib helps to reduce the levels of this oncometabolite, thereby slowing the growth of the cancer cells.
Related Terms
- Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow.
- Isocitrate Dehydrogenase 2 (IDH2): An enzyme that, when mutated, can lead to the development of certain types of cancer.
- Kinase Inhibitor: A type of drug that works by blocking the action of a specific enzyme, thereby inhibiting the growth of cancer cells.
See Also
External links
- Medical encyclopedia article on Enasidenib
- Wikipedia's article - Enasidenib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski